-
Sino Biological Completes Acquisition of SignalChem Biotech
29 Apr 2024 19:56 GMT
China-based Sino Biological, a biotech company specializing in research reagents … acquisition of Vancouver-based SignalChem Biotech (SCB) in a deal valued … scientists from basic research through drug discovery and development, according to …
-
Japan's Ono pays $2.4B for Qinlock-maker Deciphera as biotech readies another approval run
29 Apr 2024 19:23 GMT
… both the approved cancer drug Qinlock and another candidate … the Waltham, Massachusetts-based biotech’s Friday closing price … Europe, and strengthen kinase drug discovery research,” Ono’s … gastrointestinal stromal tumor (GIST) drug Qinlock. The kinase inhibitor …
-
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding
29 Apr 2024 17:02 GMT
… Origincell (Shanghai, China), Vazyme Biotech (Nanjing, China), and STOmics … military. Targeting Chinese-based biotechs would heavily affect the … -affiliated companies in the biotech and pharma sector in … ’s negative effects on drug developers. Share values of …
-
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
29 Apr 2024 17:37 GMT
MorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment.
Myelofibrosis is a type of blood cancer characterized by the buildup of scar tissue, called “fibrosis,” in the bone marrow.
…
-
Safety Concerns with MorphoSys’ Blood Cancer Drug Could Mar $2.9B Novartis Bu...
29 Apr 2024 15:53 GMT
… myelofibrosis drug pelabresib, which could potentially complicate the biotech’s … regulatory submission for the drug candidate is scheduled for … pelabresib, showing that the drug failed to hit one … the same time, the drug combo was unable to significantly …
-
STAT+: House bill aimed at Chinese biotechs is advancing
29 Apr 2024 15:37 GMT
… the science and politics driving biotech today? Sign up to … Pharmaceuticals, a maker of cancer drugs, for $2.4 billion. … said their targeted cancer drug Enhertu showed a statistically … emerging gene-editing technology. The drug, called PM359, will be …
-
STAT+: Ono Pharmaceutical to acquire Deciphera Pharma, maker of cancer drugs, for $2.4 billion
29 Apr 2024 15:37 GMT
… Boston-based maker of cancer drugs, for $2.4 billion.
… stock price.
Deciphera markets a drug called Qinlock for patients with … company is developing a second drug to treat tenosynovial giant … coverage and analysis of the biotech sector — by subscribing to …
-
FDA approves Boston biotech’s drug for ultra-rare disease of immune system
29 Apr 2024 15:04 GMT
The Food and Drug Administration has approved a Boston biotech’s drug for an … placebo, according to X4. The drug comes in capsules.
“The approval …
-
WV Bioscience Summit to Highlight Medtech, Biotech Development In West Virginia in Huntington May 29th
29 Apr 2024 14:55 GMT
… as those working in the biotechnology sector. Additionally, we’ll feature … transformative AI platform to accelerate drug discovery;
WV School of Osteopathic …
-
Deciphera to be acquired by Japanese drug firm for $2.4 billion
29 Apr 2024 14:05 GMT
Deciphera Pharmaceuticals, a Waltham cancer biotech, said Monday it will … Food and Drug Administration approved Deciphera’s drug Qinlock for adult … have already tried three other drugs for that form of …
She said Deciphera’s drug targets a broad spectrum of …